Skip to main navigation Skip to search Skip to main content

IQVIA: A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimers Disease

Project: Research

Project Details

StatusFinished
Effective start/end date08/7/23 → 03/18/26

Funding

  • Biogen MA Incorporated: $31,370.50